Answers In CME

•

频道 • 6 个节目

生命科学

生命科学

一周一更
生命科学

生命科学

一周一更
生命科学

生命科学

一周一更
生命科学

生命科学

一周一更
生命科学

生命科学

一周一更
生命科学

生命科学

一周一更

5月29日

Emma Guttman-Yassky, MD, PhD - Taking a New Approach to Relieving Atopic Dermatitis: The Evidence for OX40/OX40L Therapies

Please visit answersincme.com/CKC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the evolving role of OX40/OX40L-targeted monoclonal antibodies (mAbs) for the treatment of moderate to severe atopic dermatitis.Upon completion of this activity, participants should be better able to: Recognize the rationale for targeting OX40/OX40L in the treatment of moderate to severe atopic dermatitis (AD); Review the clinical profiles of OX40/OX40L-targeted monoclonal antibodies in treating moderate to severe AD; and Outline clinical considerations for the future integration of OX40/OX40L-targeted mAbs into treatment plans for moderate to severe AD.

5月29日

•

15 分钟
4月2日

Nathan Falk, MD, MBA, FAAFP - Making Sense of Type 2 Inflammation Crosstalk in Chronic Diseases: Perspectives on Improving Emergency and Primary Care Collaboration

Please visit answersincme.com/SFM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in family and emergency medicine discuss collaborative strategies for the optimal management of type 2 inflammatory diseases. Upon completion of this activity, participants should be better able to: Specify how type 2 inflammation contributes to the pathophysiology of chronic type 2 inflammatory diseases; Recognize the cardinal signs and symptoms of diseases presenting with type 2 inflammation; Apply treatment considerations for patients with multiple type 2 inflammatory diseases; and Outline strategies for optimizing care coordination for patients with type 2 comorbidities across providers and settings.

4月2日

•

17 分钟
5月29日

Aditya Bardia, MD / Joyce O'Shaughnessy, MD - Expert-Guided Approaches to Sequencing Strategies With ADCs in HR+, HER2- mBC

Please visit answersincme.com/860/27391-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts discuss how the available evidence informs sequencing strategies with antibody-drug conjugates for the optimization of care in HR+, HER2- metastatic breast cancer. Upon completion of this activity, participants should be better able to: Review the expert recommendations regarding a sequential approach to the use of ADCs for HR+, HER2- metastatic breast cancer (mBC) management; and Outline evidence-based clinical strategies to enhance a sequential therapeutic approach in real-world patient populations.

5月29日

•

27 分钟
6月12日

Nicholas J. Silvestri, MD - Transforming Outcomes for Patients With gMG Through Enhanced Disease Control: A Focus on FcRn Antagonists

Please visit answersincme.com/BFK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses strategies to optimally incorporate FcRn antagonists into care plans for patients with generalized myasthenia gravis (gMG). Upon completion of this activity, participants should be better able to: Describe the disease burden of generalized myasthenia gravis (gMG); Review the evidence for the use of neonatal fragment crystallizable receptor (FcRn) antagonists in gMG; and Outline strategies to optimally incorporate FcRn antagonists into the care of patients with gMG.

6月12日

•

14 分钟
2024/12/17

Sunandana Chandra, MD, MS - Practical Guidance on Managing Adverse Events Associated With Immunotherapy Regimens for Nonmelanoma Skin Cancers

Please visit answersincme.com/WJM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses strategies for patient-centered management of immune-related adverse events (AEs) in patients receiving immunotherapy for nonmelanoma skin cancer (NMSC). Upon completion of this activity, participants should be better able to: Identify counseling strategies to educate patients and caregivers about AEs related to immunotherapy regimens for melanoma and NMSC; Describe monitoring schedules for short- and long-term immunotherapy-associated AEs; and Outline multidisciplinary management strategies for immunotherapy-associated AEs in dermatologic malignancies. This activity is intended for US healthcare professionals only.

2024/12/17

•

14 分钟
2024/07/04

Ticiana Leal, MD - Squaring Off With Squamous NSCLC: The Latest Evidence and Guidance on Chemoimmunotherapy Options

Please visit answersincme.com/UWE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in lung cancer discusses chemoimmunotherapy treatment of advanced squamous cell non-small cell lung cancer without molecular alterations. Upon completion of this activity, participants should be better able to: Describe the clinical profiles of approved chemoimmunotherapy combinations for treatment of patients with advanced squamous cell non-small cell lung cancer (NSCLC) without molecular alterations; Review clinical factors for individualizing first-line treatment of patients with advanced squamous cell NSCLC; and Identify real-world factors that impact treatment selection for patients with advanced squamous cell NSCLC. This activity is intended for US healthcare professionals only.

2024/07/04

•

19 分钟
2024/11/29

Erin Barrett (Wei), MD - Focusing on the Patient to Enhance Therapeutic Care: Advancing Early Diagnosis and Management of Bullous Pemphigoid

Please visit answersincme.com/ZPD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatologic diseases discusses the diagnosis and treatment of bullous pemphigoid. Upon completion of this activity, participants should be better able to: Review the clinical impact of bullous pemphigoid (BP) on patients; Outline diagnostic approaches to enhance the timely identification of patients with BP; and Identify clinical advances that may evolve the therapeutic paradigm for patients with BP.

2024/11/29

•

15 分钟
$David E. Griffith, MD - Guiding Principles in the Management of Refractory Mycobacterium Avium Complex (MAC) Pulmonary Disease: Casing the Evidence to Inform Practical Care$

4月7日

David E. Griffith, MD - Guiding Principles in the Management of Refractory Mycobacterium Avium Complex (MAC) Pulmonary Disease: Casing the Evidence to Inform Practical Care

Please visit answersincme.com/FXP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonary infectious disease discusses management of refractory Mycobacterium avium complex (MAC) pulmonary disease. Upon completion of this activity, participants should be better able to: Identify patients with refractory Mycobacterium avium complex (MAC) pulmonary disease in a timely manner; Review guideline-recommended therapeutic approaches to enhance the treatment plan for patients with refractory MAC pulmonary disease; and Outline clinical strategies to optimize long-term care for patients with refractory MAC pulmonary disease.

4月7日

•

19 分钟
$Stephen M. Ansell, MD, PhD / Caron Jacobson, MD, MMSc - Navigating a New Treatment Algorithm for Patients With Relapsed/Refractory Follicular Lymphoma: Where Do CD20 x CD3 Bispecific Antibodies Fit In?$

2024/02/26

Stephen M. Ansell, MD, PhD / Caron Jacobson, MD, MMSc - Navigating a New Treatment Algorithm for Patients With Relapsed/Refractory Follicular Lymphoma: Where Do CD20 x CD3 Bispecific Antibodies Fit In?

Please visit answersincme.com/XHR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in follicular lymphoma discuss the integration of bispecific antibodies into the treatment of relapsing/refractory follicular lymphoma. Upon completion of this activity, participants should be better able to: Review the clinical profiles of novel CD20 x CD3 bispecific antibodies (BsAbs) for relapsing/refractory follicular lymphoma (R/R FL); Describe patient-centered strategies to manage BsAb-associated adverse events in R/R FL; and Outline evidence-based multidisciplinary strategies for optimal integration of BsAbs in the treatment plans of patients with R/R FL.

2024/02/26

•

16 分钟
2月17日

James E. Galvin, MD, MPH - Voyage Through AD: From Early Detection to Collaborative Care

Please visit answersincme.com/WKB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses early-stage Alzheimer’s Disease (AD). Upon completion of this activity, participants should be better able to: Describe the multidisciplinary process of screening patients for early-stage AD; Describe the role primary care providers play in the multidisciplinary process of diagnosing patients with early-stage AD; and Outline strategies for counseling patients and caregivers about early intervention for early-stage AD.

2月17日

•

14 分钟

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for busy healthcare professionals to cover the diagnosis, treatment, followup, and clinical management of various medical conditions. Earning your CME/CE credit has never been faster or easier.